On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session, extending a multi-day rally.

On the news front, BOCOM International recently issued a research report identifying WuXi XDC as a top pick with strong investment value within the high-growth bioconjugate CRDMO track. The broader CXO sector has continued to strengthen, with WuXi AppTec up 2.33%, WuXi Biologics up 1.6%, and Insilico Medicine up 9.0% on the same day, forming a sector resonance effect. In addition, the pharmaceutical sector has seen a wave of buybacks and insider purchases since Q2, with over 100 biopharma companies across A-shares and H-shares disclosing repurchase plans, with innovative drug companies serving as the core driving force behind this trend.

Furthermore, WuXi XDC's subsidiary Dongyao Pharma signed a process development and manufacturing services agreement with WuXi Biologics on June 16, covering 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)